Published on
December 23, 2022

Psilocybin for Alcohol Dependence Trial by B.More Principal Investigator, Michael Bogenschutz, Recognized as Pivotal Psychedelic Breakthrough for 2022

Greenwich, Connecticut, December 20, 2022 – B.More Inc., a 501(c)(3) non-profit, clinical-stage biopharmaceutical company focused on the development of psychedelic medicines for substance abuse disorders, is proud to announce that the psilocybin for alcohol use dependence (AUD) trial by its Principal Investigator, Michael Bogenschutz, Director of the NYU Langone Center for Psychedelic Medicine, has been cited by the publication PSYCH as one of the key developments in psychedelics for 2022.

“The publication of Michael’s trial in JAMA Psychiatry, with its reported 83% average reduction in alcohol consumption among heavy drinkers, was one of the biggest psychedelics stories of the year, so we are not at all surprised at this acknowledgement of the significance of the trial’s findings”, said Carey Turnbull, B.More Co-founder and CEO. “B.More’s psilocybin for AUD Phase 2b clinical trial will be critical in advancing better treatment options for the 14.5 million Americans struggling with AUD and we are thrilled to have Michael Bogenschutz leading that work as our Principal Investigator.”

B.More’s Phase 2b, multicenter, randomized, double blind, active placebo-controlled trial will examine the efficacy and safety of synthetic psilocybin (SYNP-101) for the treatment of moderate to severe AUD. The trial plans to enroll a total of 210 participants who will receive psychotherapy and one administration of 30mg of SYNP-101 or the active placebo, niacin. The primary objective of the trial is to determine the efficacy of SYNP-101, compared to niacin, in reducing alcohol consumption during 24-weeks following treatment.

About B.More

Founded in 2017 by Carey and Claudia Turnbull, B.More is a 501(c)(3) non-profit, clinical-stage biopharmaceutical company with a mission to develop better treatment options for those struggling with alcohol use disorder and other substance use disorders. Named after Claudia Turnbull’s brother, Brett Moore, who died of a drug overdose 50 years ago, B.More is focused on the development and commercialization of psychedelic medicines that offer the potential to dramatically improve the lives of those for whom current treatment options have not proved effective. With researchers at the NYU School of Medicine, B.More is advancing clinical research to help these individuals and their loved ones live a better tomorrow.

For more information, please visit

Media inquiries:

Contact: Christopher Koddermann

Tel.: +41 (79) 434 25 78